Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus cadonilimab with chemotherapy as first-line treatment for metastatic pancreatic cancer (Phase Ib/II)
CTR20244170Phase 2Active
- Sponsor
- CTTQ-Akeso
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, cadonilimab in pancreatic adenocarcinoma (PDAC), sponsored by CTTQ-Akeso. Started Jan 2025; status: active.
02
Drugs
ivonescimabcadonilimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20244170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244170.